Recently, intracellular Separase proteolytic activity was identified as a potential marker of molecular response, BCR::ABL1 positivity and proliferation of CD34+ cells in TKI-treated CML patients [13]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.